Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 15/20 | 0.58 |
| ▸ | KDR | P35968 | 15/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17157034 | 0.99 | KDR (0.57) | FGFR3KDRFYN | |
| SCHEMBL13407683 | 0.89 | FGFR3 (0.60) | FGFR3KDR | |
| Hydrochloric Acid SCHEMBL17157041 | 0.89 | FGFR3 (0.59) | FGFR3KDR | |
| SCHEMBL13407665 | 0.88 | KDR (0.61) | FGFR3KDRFLT3 | |
| SCHEMBL3590287 | 0.87 | KDR (0.63) | FGFR3KDRFLT3 | |
| SCHEMBL13407732 | 0.83 | FGFR3 (0.58) | FGFR3KDRFYN | |
| SCHEMBL13407724 | 0.83 | FGFR3 (0.53) | FGFR3KDRFYN | |
| SCHEMBL3586444 | 0.82 | FGFR3 (0.54) | FGFR3KDRFLT3 | |
| SCHEMBL3581751 | 0.82 | FGFR3 (0.61) | FGFR3KDRFLT3FYN | |
| SCHEMBL3590921 | 0.82 | FGFR3 (0.56) | FGFR3KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | claimed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | FGFR3 6/4885KDR 7/4885FLT3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.